Contribute Try STAT+ Today

Cancer clinical trials have seen a drastic drop in patient enrollment since the onset of the Covid-19 pandemic, driven in part by some institutions pausing recruitment in order to prevent the spread of the virus.

Bringing enrollment numbers back up safely will prove crucial for researchers running clinical trials and the drug companies that sponsor them. In a new paper published Thursday in JAMA Oncology, researchers surveyed cancer patients to gauge their willingness to participate in clinical trials once enrollment restrictions lifted, even if Covid-19 was still spreading in their community.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.